Sign up Australia
Proactive Investors - Run By Investors For Investors

CTI BioPharma reports failure of Phase 3 non-Hodgkins lymphoma trial

Leah Rush Cann, a widely-followed analyst with Oppenheimer, is still keeping her Outperform rating on CTI BioPharma, but cutting her stock price target to US$6 from US$7
Cancer cells
Shares in the thinly-traded biopharma group were halted in pre-market trading

CTI BioPharma Corp (NASDAQ:CTIC) delivered crushing news today with the report that its final stage trial for a treatment aimed at the blood cancer non-Hodgkin lymphoma failed to meet its main objectives.

The Phase III trial evaluated the drug, Pixuvri combined with Roche’s rituximab in comparison to gemcitabine combined with rituximab in patients with aggressive B-cell non-Hodgkin lymphoma.

The results found that the use of Pixuvri failed to meet its primary endpoint of an improvement in progression-free survival, according to the company.  

“We are disappointed with the outcome of the PIX 306 trial and will proceed to conduct a thorough review of clinical data to assess the next steps for the PIXUVRI program," said Dr Adam Craig, CEO of CTI BioPharma.

Shares in the thinly-traded biopharma group were halted in pre-market trading, but later resumed trading to fall 14% in the morning session to US$4.47.

Given the explosive nature of the announcement, analysts also moved to change their projections for the company.

Oppenheimer’s Leah Rush Cann, for example, reduced CTI’s revenue forecast by 37% for 2020 and by 20.9% in 2021. She also slashed its revenue forecast by 15.8% in 2022; 12.7% in 2023; and 13.9% in 2024. “As a result of PIX306 not meeting its primary endpoint, we are removing Pixuvri from our CTI Biopharma revenue estimated through 2024,” Rush Cann wrote in a note to investors.

"Our 2018 outlook is unchanged for CTI BioPharma, and 2019 is only modestly impacted," she added.

Rush Cann is keeping an Outperform rating on the stock and is only reducing her stock price target to US$6 from US$7. 

She maintains a relatively rosy view on CTI BioPharma, which is not yet profitable, as she is bullish on its compound pacritinib, which is used for the treatment of patients with myelofibrosis and set to hit the market by 2020.

The biggest risk to the stock is if pacritinib fails to obtain approval by the US Food and Drug Administration, according to Rush Cann’s analysis. “Under the scenario that [pacritinib] fails to be FDA approved, we estimate CTI BioPharma’s stock could have little value,” she wrote.

The so-called PIX 306 trial enrolled 312 patients who had relapsed cases of non-Hodgkin lymphoma and were ineligible for stem cell transplants.

Non-Hodgkin lymphoma is a cancer that begins in the lymphocytes, a type of white blood cell, and its range of usual treatments include chemotherapy, radiation and stem cell transplants.

-- updated with renewed share price movement as well as analyst commentary

View full CTIC profile View Profile

CTI BioPharma Corp Timeline

Related Articles

picture of cannabis plants
March 24 2018
Control of the supply chain offers operational advantages and financial benefits.
Oncoprex
Thu
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use